Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment. (October 2021)

• Record Type: Journal Article
• Authors: Landi, C.; Vantaggiato, L.; Shaba, E.; Cameli, P.; Carleo, A.; d'Alessandro, M.; Bergantini, L.; Bargagli, E.; Bini, L.
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 70(2021)
• Publication Date: 2021-10
• Subjects: Mepolizumab -- Benralizumab -- Redox proteomics -- Serum -- Severe eosinophilic asthma; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2021.102060
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 ± 1.2; benralizumab 0; p < 0.0001), improving the quality of life and lung function parameters (FEV1%: mepolizumab 87.1 ± 21.5; benralizumab 89.7 ± 15, p < 0.04). Here we report a preliminary redox proteomic study highlighting the level of oxidative burst present in serum from patients before and after one month of both treatments. Our results highlighted apolipoprotein A1 oxidation after Mepolizumab treatment, that could be related to HDL functionality and could represent a potential biomarker for the treatment. On the other hand, after one month of Benralizumab we detected higher oxidation levels of ceruloplasmin and transthyretin, considered an important oxidative stress biomarker which action help to maintain redox homeostasis. Highlights: Mepolizumab and Benralizumab are biological drugs for severe asthma disease. We report a preliminary redox proteomic study of serum before and after 1 month of benralizumab and mepolizumab treatment. APOAI oxidation could represent a biomarker for mepolizumab treatment. Ceruloplasmin and transthyretin are considered important oxidative stress biomarkers for benralizumab treatment.